Duloxetine for premenstrual dysphoric disorder: A pilot study

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 4, 2008, Pages 517-521

  Mazza, Marianna ^a   Harnic, Desiree ^a   Catalano, Valeria ^a   Janiri, Luigi ^a   Bria, Pietro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Duloxetine; Menstrual cyde; PMDD; Premenstrual dysphoric disorder; SNRI

Indexed keywords

DULOXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; THIOPHENE DERIVATIVE;

ADULT; ANOREXIA; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; INSOMNIA; LUTEAL PHASE; MAJOR CLINICAL STUDY; MOOD DISORDER; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; RATING SCALE; SELF-RATING DEPRESSION SCALE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; AFFECT; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; HOSPITALIZATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TIME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AFFECT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSION; FEMALE; HUMANS; PILOT PROJECTS; PREMENSTRUAL SYNDROME; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 40649090873     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.4.517     Document Type: Article

References (24)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR). American Psychiatric Press, Washington, DC; 2000
2. Schwärzler B, Hautzinger M. Premenstrual dysphoric disorder: a proposed diagnostic method of a distinct affective disorder. Der Nervenarzt 2002;73(1):65-70
3. Mchichialami KH, Tahiri SM, Moussaoui D, et al. Assessment of premenstrual dysphoric disorder symptoms: population of women in Casablanca. Encephale 2002;28(6):525-30
4. Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32
5. Cross GB, Marley J, Miles H, et al. Changes in nutrient intake during the menstrual cycle of overweight women with premenstrual syndrome. Br J Nutr 2001;85(4):475-82
6. Pearlstein T, Stone AB. Premenstrual syndrome. Psychiatr Clin North Am 1998;21:577-90
7. Bianchi-Demicheli F, Lüdicke F, Lucas H, et al. Premenstrual dysphoric disorder: current status of treatment. Swiss Med Weekly 2002;132:574-8
8. Hsiao MC, Liu CY. Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. Psych Clin Neurosci 2003;57:317-21
9. Freeman EW, Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999;156:1403-8
10. Pearlstein TB, Bellew KM, Endicott J, et al. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomised, double-blind, placebo-controlled trial. J Clin Psychiatry 2005;7:53-60
11. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-33
12. World Health Organization. International Classification of Disease (10th edition, ICD-10). WHO; 1994
13. Steiner M, Streiner DL, Steinberg, et al. The measurement of premenstrual mood symptoms. J Aff Disord 1999;53:269-73
14. Steiner M, Streiner DL, Pham B. Validation of a revised visual analog scale for premenstrual mood symptoms: results from prospective and retrospective trials. Can J Psychiatry 2005;50:327-32
15. Mishell DR. Premenstrual disorders: epidemiology and disease burden. Am J Manag Care 2005;11:S473-9
16. Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000;61(S12):17-21
17. Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001;98:737-44
18. Blake F, Salkovskis P, Gath D, et al. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res 1998;45:307-18
19. Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-re-uptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000;356:1131-6
20. Landen M, Nissbrandt H, Allgulander C, et al. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007;32:153-61
21. Cohen LS, Soares CN, Yonkers KA, et al. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 2004;66:707-13
22. Ramos MG, Hara C, Rocha FL. Duloxetine treatment of premenstrual dysphoric disorder: case reports. Progr Neuropsychopharmacol Biol Psychiatry Epub 2007 Sep 15
23. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 2007;21(7):581-609
24. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53